Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer：A Randomized Controlled Clinical Trial

NCT05994339 is registered in ClinicalTrials.gov with Laibin People's Hospital as lead sponsor.

NCT NCT05994339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05994339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer：A Randomized Controlled Clinical Trial
Lead sponsor
Laibin People's Hospital
Phase
Phase 2/3
Overall status
Unknown status
Start date
September 1, 2023
Completion date
December 8, 2025
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer stage iii